vs
AIM ImmunoTech Inc.（AIM）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是AIM ImmunoTech Inc.的9424.4倍（$197.9M vs $21.0K）。REPLIGEN CORP净利率更高（6.7% vs -19881.0%，领先19887.7%）。REPLIGEN CORP同比增速更快（13.6% vs -53.3%）。过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -27.5%）
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AIM vs RGEN — 直观对比
营收规模更大
RGEN
是对方的9424.4倍
$21.0K
营收增速更快
RGEN
高出67.0%
-53.3%
净利率更高
RGEN
高出19887.7%
-19881.0%
两年增速更快
RGEN
近两年复合增速
-27.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0K | $197.9M |
| 净利润 | $-4.2M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -14057.1% | 9.0% |
| 净利率 | -19881.0% | 6.7% |
| 营收同比 | -53.3% | 13.6% |
| 净利润同比 | 30.0% | 143.9% |
| 每股收益（稀释后） | $-6.46 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIMRGEN
| Q4 25 | $21.0K | $197.9M | ||
| Q3 25 | $26.0K | $188.8M | ||
| Q2 25 | $25.0K | $182.4M | ||
| Q1 25 | $16.0K | $169.2M | ||
| Q4 24 | $45.0K | $174.1M | ||
| Q3 24 | $35.0K | $154.9M | ||
| Q2 24 | $50.0K | $154.1M | ||
| Q1 24 | $40.0K | $151.3M |
净利润AIMRGEN
| Q4 25 | $-4.2M | $13.3M | ||
| Q3 25 | $-3.3M | $14.9M | ||
| Q2 25 | $-2.8M | $14.9M | ||
| Q1 25 | $-3.7M | $5.8M | ||
| Q4 24 | $-6.0M | $-30.3M | ||
| Q3 24 | $-3.7M | $-654.0K | ||
| Q2 24 | $-1.8M | $3.3M | ||
| Q1 24 | $-5.8M | $2.1M |
毛利率AIMRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率AIMRGEN
| Q4 25 | -14057.1% | 9.0% | ||
| Q3 25 | -9411.5% | 8.9% | ||
| Q2 25 | -10584.0% | 7.6% | ||
| Q1 25 | -22618.8% | 3.9% | ||
| Q4 24 | -13011.1% | -17.7% | ||
| Q3 24 | -12825.7% | -5.1% | ||
| Q2 24 | -7388.0% | 1.0% | ||
| Q1 24 | -14335.0% | 1.3% |
净利率AIMRGEN
| Q4 25 | -19881.0% | 6.7% | ||
| Q3 25 | -12630.8% | 7.9% | ||
| Q2 25 | -11176.0% | 8.2% | ||
| Q1 25 | -23156.3% | 3.4% | ||
| Q4 24 | -13260.0% | -17.4% | ||
| Q3 24 | -10571.4% | -0.4% | ||
| Q2 24 | -3672.0% | 2.2% | ||
| Q1 24 | -14542.5% | 1.4% |
每股收益（稀释后）AIMRGEN
| Q4 25 | $-6.46 | $0.24 | ||
| Q3 25 | $1.57 | $0.26 | ||
| Q2 25 | $-3.68 | $0.26 | ||
| Q1 25 | $-0.05 | $0.10 | ||
| Q4 24 | $-21.80 | $-0.55 | ||
| Q3 24 | $-6.00 | $-0.01 | ||
| Q2 24 | $-3.00 | $0.06 | ||
| Q1 24 | $-0.12 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $767.6M |
| 总债务越低越好 | $4.5M | $542.2M |
| 股东权益账面价值 | $-9.8M | $2.1B |
| 总资产 | $5.8M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资AIMRGEN
| Q4 25 | $3.0M | $767.6M | ||
| Q3 25 | $2.4M | $748.7M | ||
| Q2 25 | $835.0K | $708.9M | ||
| Q1 25 | $2.2M | $697.2M | ||
| Q4 24 | $4.0M | $757.4M | ||
| Q3 24 | $7.2M | $784.0M | ||
| Q2 24 | $10.1M | $809.1M | ||
| Q1 24 | $10.9M | $780.6M |
总债务AIMRGEN
| Q4 25 | $4.5M | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | $525.6M | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $3.3M | — |
股东权益AIMRGEN
| Q4 25 | $-9.8M | $2.1B | ||
| Q3 25 | $-6.1M | $2.1B | ||
| Q2 25 | $-6.5M | $2.1B | ||
| Q1 25 | $-3.9M | $2.0B | ||
| Q4 24 | $-1.3M | $2.0B | ||
| Q3 24 | $2.9M | $2.0B | ||
| Q2 24 | $6.1M | $2.0B | ||
| Q1 24 | $4.8M | $2.0B |
总资产AIMRGEN
| Q4 25 | $5.8M | $2.9B | ||
| Q3 25 | $5.5M | $2.9B | ||
| Q2 25 | $4.1M | $2.9B | ||
| Q1 25 | $6.2M | $2.9B | ||
| Q4 24 | $8.6M | $2.8B | ||
| Q3 24 | $13.6M | $2.8B | ||
| Q2 24 | $15.7M | $2.9B | ||
| Q1 24 | $16.2M | $2.8B |
负债/权益比AIMRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流AIMRGEN
| Q4 25 | $-2.0M | $25.7M | ||
| Q3 25 | $-5.1M | $48.1M | ||
| Q2 25 | $-1.5M | $28.6M | ||
| Q1 25 | $-2.4M | $15.0M | ||
| Q4 24 | $-4.0M | $39.2M | ||
| Q3 24 | $-3.1M | $49.3M | ||
| Q2 24 | $-3.0M | $42.2M | ||
| Q1 24 | $-4.8M | $44.7M |
自由现金流AIMRGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M | ||
| Q1 24 | — | $36.4M |
自由现金流率AIMRGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% | ||
| Q1 24 | — | 24.0% |
资本支出强度AIMRGEN
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 5.5% |
现金转化率AIMRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
